Endo Presents Dupuytren Contracture Data at the IFSSH and IFSHT Triennial Congress
Endo, Inc. (OTCQX: NDOI) announced today that data related to the use of XIAFLEX® (collagenase clostridium histolyticum, or ...
Endo, Inc.: Endo Presents Dupuytren Contracture Data at the IFSSH and IFSHT Triennial Congress
Endo, Inc. (OTCQX: NDOI) announced today that data related to the use of XIAFLEX® (collagenase clostridium histolyticum, or CCH) for the treatment ...
The Victoria Advocate12d
Endo Presents Dupuytren Contracture Data at the IFSSH and IFSHT Triennial Congress
MALVERN, Pa., March 24, 2025 /CNW/ -- Endo, Inc. (OTCQX: NDOI) announced today that data related to the use of XIAFLEX ® (collagenase clostridium histolyticum, or CCH) for the treatment of ...
News-Medical.Net on MSN3d
Understanding the phases and treatment options for Peyronie’s disease
The review article titled"Current insights and future directions in Peyronie's disease management: A narrative review", was ...
EurekAlert!3d
Peyronie's disease management Current insights & Future directions
Peyronie's disease (PD) causes penile curvature. Its etiology is multifactorial, involving microtrauma and genetic factors.
Longview News-Journal24d
Endo Announces Peyronie's Disease Presentation at the Annual Meeting of the Southeastern Section of the American Urological Association
March 12, 2025 /PRNewswire/ -- Endo, Inc. (OTCQX: NDOI) announced today that a post hoc data analysis of a Phase 3 clinical trial of XIAFLEX ® (collagenase clostridium histolyticum, or CCH ...